Exelixis, Inc. (NASDAQ:EXEL) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis' investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a phase 3 pivotal trial for the treatment of patients with head and neck squamous cell carcinoma (HNSCC), and zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for the treatment of patients with renal cell carcinoma (RCC).
This press release features multimedia. View the full release here:
